22 results
8-K
EX-99.1
CGTX
Cognition Therapeutics Inc
26 Mar 24
Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update
7:12am
-to-moderate dementia with Lewy bodies (DLB); topline results expected in 2H2024
Initiated site activation and recruitment in Phase 2 START Study in early
424B5
CGTX
Cognition Therapeutics Inc
13 Mar 24
Prospectus supplement for primary offering
4:04pm
(COG0203) study of CT1812 in patients with early-stage AD. We received clearance from the FDA to proceed with the START clinical trial and recruitment has
424B5
CGTX
Cognition Therapeutics Inc
11 Mar 24
Prospectus supplement for primary offering
4:06pm
-stage AD. We received clearance from the FDA to proceed with the START clinical trial and recruitment has commenced. We intend to enroll 540 adults
8-K
EX-99.1
zsdfcyfzkc omtml20x
4 Jan 24
Other Events
4:21pm
8-K
EX-99.1
cvzh 1i8yb
2 Nov 23
Cognition Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
7:41am
8-K
EX-99.1
w1o7 vobfafr1
8 Aug 23
Cognition Therapeutics Reports Second Quarter 2023 Financial Results and Business Update
7:05am
DEF 14A
ry3p0p1
25 Apr 22
Definitive proxy
5:28pm
S-1
EX-10.31
s9qw1ivl
19 Jul 21
IPO registration
7:02am
S-1
EX-10.24
w0m89z47vmz6
19 Jul 21
IPO registration
7:02am
S-1
EX-10.25
n79 w4iahb
19 Jul 21
IPO registration
7:02am
S-1
EX-10.32
rynf9vbe0vdzdnd9p90n
19 Jul 21
IPO registration
7:02am
S-1
EX-10.33
02li9isu0azd holm3re
19 Jul 21
IPO registration
7:02am
S-1
EX-10.27
grid3wu70gxit3m
19 Jul 21
IPO registration
7:02am
DRS/A
EX-10.24
a74rb
23 Jun 21
Draft registration statement (amended)
12:00am
DRS/A
EX-10.21
622kmwuky6ws52rfgj
23 Jun 21
Draft registration statement (amended)
12:00am
DRS/A
EX-10.30
abl2oc1d
23 Jun 21
Draft registration statement (amended)
12:00am
DRS/A
EX-10.22
4yhcvdm0whhtaitt
23 Jun 21
Draft registration statement (amended)
12:00am